How Big Is the Cell Therapy CDMO Market | Industry Trends & Forecast 2025

Q: What is the current size and forecast of the cell therapy CDMO market?

The market was valued at USD 2.8 billion in 2024 and is projected to reach USD 7.4 billion by 2031 at a CAGR of 14.2%.

Q: What drives outsourcing to CDMOs?

Specialized GMP expertise, cost efficiency, capacity scaling, and regulatory support.

Q: Which therapy types are most outsourced?

CAR-T, stem cell, and gene-modified T-cell therapies dominate CDMO workload.

Q: What challenges does the CDMO space face?

Manufacturing complexity, supply chain coordination, and facility capacity constraints.

Q: How does 6W market outlook report help businesses in making decisions?

6W monitors the market across 60+ countries Globally, publishing an annual market outlook report that analyses trends, key drivers, Size, Volume, Revenue, opportunities, and market segments. This report offers comprehensive insights, helping businesses understand market dynamics and make informed decisions.

Q: Do you also provide customisation in the market study?

Yes, we provide customisation as per your requirements. To learn more, feel free to contact us on sales@6wresearch.com

Code: MTA4765

Publication Date: Jul 2025

How big is the Cell Therapy CDMO Market?

According to 6Wresearch internal database and industry insights, the cell therapy CDMO (Contract Development and Manufacturing Organization) market was valued at approximately USD 2.8 billion in 2024 and is projected to reach USD 7.4 billion by 2031, growing at a CAGR of 14.2% during the forecast period.

This growth is driven by the surge in cell and gene therapy pipelines, high demand for GMP-compliant manufacturing support, and outsourcing preferences among biotech firms.

Key Growth Drivers of the Cell Therapy CDMO Market

Increasing volume of CAR-T, TCR-T, and stem cell therapy clinical trials
High capital investment required for in-house GMP facilities
Expertise demands for complex scaling, vector production, and cell expansion
Rising collaboration between biotech innovators and CDMO providers
Regulatory emphasis on quality, traceability, and process validation

Cell Therapy CDMO Market Trends

Cell therapy CDMO market is moving toward vertically integrated service offerings encompassing development, regulatory support, analytics, and commercial-scale manufacturing. Outsourcing strategic alliances are being established to co-develop proprietary platforms and streamline technology transfer. Single-use bioprocessing systems and closed-vessel automation are gaining prominence to reduce contamination risks and improve batch consistency. Providers are also offering modular fill finish and logistics services to support global distribution of therapies.

Emerging Developments in the Cell Therapy CDMO Market

The new advances would involve the use of AI-based digital twins toward the maximization of production output and process management. There are multi-product manufacturing sites being established to produce pipeline mix of autologous and allogeneic products. Chain-of-identity solutions based on blockchain blockchain-based batch certification are in pilot phase. Spatial bioreactors allowing real-time monitoring and scalability are being presented. Besides, CDMOs are teaming up with technology firms to come up with decentralized GMP pods that can produce cell therapy products at point of care.